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ABSTRACT  
OBJECTIVE: To assess the effects of oral ingestion of the green tea polyphenol 
epigallocatechin gallate (EGCG) on cognitive performance, mood and localised cerebral 
blood flow (CBF) parameters in healthy human adults. 
METHOD: In this double blind, placebo controlled, cross-over study 27 healthy adults 
received placebo and two doses (135 mg and 270 mg) of EGCG in counterbalanced order on 
separate days. Following a 45-min resting absorption period participants performed a 
selection of computerised cognitive tasks that activate the frontal cortex for a further 42 
minutes. CBF and haemodynamics, as indexed by concentration changes in oxygenated and 
deoxygenated haemoglobin, were assessed in the frontal cortex throughout the post-
treatment period using Near Infrared Spectroscopy (NIRS). 
RESULTS: During the post-dose task performance period the administration of 135 mg EGCG 
resulted in reduced CBF in the frontal cortex, as indexed by significantly lower 
concentrations of both oxygenated and total haemoglobin, in comparison to placebo. Heart 
rate was significantly reduced from pre- to post dose across all treatments. No significant 
differences were observed for the level of deoxygenated haemoglobin or on any of the 
cognitive performance/mood measures. 
CONCLUSIONS: These results demonstrate that a single dose of orally administered EGCG 
can modulate CBF parameters in healthy humans but that this is not associated with 
changes in cognitive performance or mood.  
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INTRODUCTION 
Epigallocatechin gallate (EGCG) is the most abundant polyphenol found in the tea plant 
(Camellia sinensis), accounting for ~10% of the dry weight of green tea leaves (Mandel et al., 
2008). Within the plant EGCG and other catechins confer protective and growth promoting 
roles, accumulating in vulnerable locations such as the seed coat, woody stem, root, and 
foliage (Forrest and Bendall, 1969). It has been suggested that the mechanisms by which tea 
catechins protect the host plant may also exert a range of protective health effects in the 
humans who consume them (Khan and Mukhtar, 2007), including possible protection 
against high blood cholesterol and high blood pressure (Taubert et al., 2007), and ischemic 
heart disease (Arts et al., 2001). 
In vitro studies suggest that EGCG has a number of properties potentially relevant to brain 
function, including effects on cholinergic transmission (Katayama et al., 2002), neurite 
outgrowth (Reznichenko et al., 2005), inflammatory parameters (Kim et al., 2007), metal 
chelation (Mandel et al., 2008) and an ability to act as an anti-oxidant (Unno et al., 2007) 
and to up-regulate endogenous antioxidant capacity (Mandel et al., 2008). In vivo studies 
utilising animal models suggest that EGCG may offer multi-faceted protection against the 
aetiology and behavioural consequences of a number of neurodegenerative diseases after 
oral administration, including Alzheimer’s disease (Koh et al., 2006; Lee et al., 2009; Rezai-
Zadeh et al., 2008) and Parkinson’s disease (Levites et al., 2001). Epidemiological studies 
also suggest that tea consumption reduces the risk of ischemia/stroke in humans (Arab et 
al., 2009) and green tea catechins (63% EGCG) have also been shown to improve cognitive 
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performance and concomitantly increase antioxidant capacity in normal rats after oral 
ingestion (Haque et al., 2004).  
One property underlying the potential cardio-vascular effects of EGCG is an ability to 
modulate blood flow parameters. Ex vivo research in isolated rat aorta suggests that EGCG 
exhibits vaso-relaxant properties (Lorenz et al., 2009; Chen et al., 2000; Alvarez et al., 2006). 
However, vaso-constriction (Sanae et al., 2002; Shen et al., 2003) and biphasic relaxant and 
constricting (Alvarez et al., 2004) properties have also been observed. Both the vaso-
relaxation and constriction have been attributed, in part, to opposite effects on endothelial 
nitric oxide (NO) production and activity (Sanae et al., 2002; Lorenz et al., 2009). With 
regards the effects of this in humans, a number of studies have demonstrated improved 
endothelial function in the periphery following tea (Shenouda and Vita, 2007; Alexopoulos 
et al., 2008; Nagaya et al., 2004) with similar effects seen following epicatechin 
administered to healthy participants (Schroeter et al., 2006) and EGCG administered to 
patients with coronary artery disease (Widlansky et al., 2007).  
Whilst the balance of evidence suggests that EGCG promotes endothelial NO synthesis, and 
therefore peripheral vaso-relaxation, it has also been shown to directly inhibit both 
inducible NO synthase (iNOS) and neuronal NO synthase (nNOS) (Chan et al., 1997; Stevens 
et al., 2002). While the effect of reducing neuronal NO production may confer 
neuroprotective properties in the face of damaging overproduction of NO during brain 
insults (Wei et al., 2004) the effects on cerebral blood flow (CBF) of EGCG related down-
regulation of nNOS during normal functioning are unknown. NO itself  is a key vaso-dilatory 
mediator in the neurovascular coupling of neuronal activity to increased blood supply in 
active tissue (Gally et al., 1990; Kitaura et al., 2007) and whilst both eNOS and nNOS are 
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found in brain tissue (Toda and Okamura, 2003) it is NO derived from nNOS which has been 
observed to make the greatest contribution to activity dependent vasodilation (Ayata et al., 
1996; Cholet et al., 1997; Kitaura et al., 2007; Santizo et al., 2000).   
Indeed, previous in vivo research with the red wine polyphenol resveratrol indicates that as 
well as up- regulating levels of eNOS (Tsai et al., 2007) resveratrol is also able to up- regulate 
nNOS (Hung et al., 2004), unlike EGCG, and as such is associated with both peripheral 
vasodilation (Rush et al., 2007; Rivera et al., 2009) and increased CBF in the frontal cortex of 
healthy humans, as measured by Near Infrared Spectroscopy (NIRS), during the 
performance of tasks that activate this brain region (Kennedy et al., 2010). To date, a small 
number of pharmacological intervention studies have also used the technique to infer 
localized brain activity (Kanamaru et al., 2008) and CBF and oxygenation (Bönöczk et al., 
2002) from changes in  haemoglobin concentrations. These include studies demonstrating 
an increased haemodynamic response to task performance following docosahexaenoic 
acid (Jackson et al., In press) and both increased CBF following single doses of resveratrol 
(Kennedy et al., 2010) and decreased CBF following a single dose of caffeine (Kennedy and 
Haskell, 2011). 
The current double-blind, placebo-controlled, balanced cross-over study therefore 
investigated the effects of oral doses of EGCG on CBF in the frontal cortex using NIRS during 
the performance of tasks that activate this brain region. Given the wide range of potential 
brain relevant parameters that might be modulated by EGCG, including blood flow and 
therefore the delivery of metabolic substrates, cognitive performance was also assessed 
during the selection of executive function/working memory and attention tasks. Heart rate 
and blood pressure were also monitored at several time points throughout the study. 
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EXPERIMENTAL METHODS 
Participants 
Twenty-seven healthy adults (11 males, 16 females, mean age 22 years, range 18-30, 23 
right handed, 4 left handed) took part in the study. A further 5 participants that failed to 
satisfactorily complete the testing procedures were replaced during the running of the study 
and prior to un-blinding. All participants attended the laboratory having fasted from 2 hours 
prior to testing. Participants were required to consume a standardised diet prior to that in 
terms of what and when they ate on day 1. They abstained from caffeine and alcohol from 
8pm the night before. All participants reported themselves to be in good health and free 
from social drugs, alcohol, prescription medication and herbal extracts/food supplements at 
each assessment. Participants who had suffered a head injury, neurological disorder or 
neuro-developmental disorder were excluded from participation, as were those who had 
any relevant food allergies or intolerances, smoked tobacco, drank excessive amounts of 
caffeine (more than 600mg day as assessed by a caffeine consumption questionnaire) or 
took illicit social drugs.  
The study received ethical approval from the Northumbria University School of Psychology 
and Sport Sciences Ethics Committee and was conducted according to the Declaration of 
Helsinki (1964). All participants gave their informed consent prior to their inclusion in the 
study. Prior to data collection this investigation was registered on the clinicaltrials.gov 
website with the following identification number: NCT00981292. 
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Treatments 
During the three study visits participants received three single-dose treatments in an order 
dictated by random allocation to a counterbalancing (Latin Square) order.  
The three treatments comprised two capsules each containing either 135 mg EGCG (94% 
pure EGCG plus 6% excipients - DSM Nutritional Products) or an inert placebo. The capsules 
were combined to give the following treatments: 
i) Inert placebo 
ii) 135mg EGCG 
iii) 270mg EGCG  
As this study was the first to investigate the cognitive and CBF effects of EGCG in humans, 
the doses utilized here are exploratory but represent the quantity of EGCG one might 
expect to achieve from ~1.5- 3 cups of green tea respectively. This is based on the 
approximation that 1 cup of green tea will yield ~90mg EGCG (Wu and Wei, 2002). 
The treatments were administered in identical size 0 gelatine capsules, which were 
prepared and coded by a third party who had no further involvement in any aspect of the 
study. No member of the investigational team was aware of the contents of the capsules 
until a blind-data review was completed. 
 
Near Infrared spectroscopy (NIRS): 
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NIRS is a non-invasive brain imaging technique in which two nominal wavelengths of light 
(~765 and 855 nm), which are differentially absorbed by oxygenated and deoxygenated 
haemoglobin respectively, are introduced through the skull via a laser emitter and 
measured, following transit through the upper surface of the cortex, by an optode placed at 
a pre-set distance from the light source (4cm in this case). Relative changes in the 
absorption of near infrared light were measured at a time resolution of 10 Hz using a 12 
channel Oxymon system (Artinis Medical Systems B.V.). The differential path-length factor 
was adjusted according to the age of the participant. Relative concentration changes in 
haemoglobins were calculated by means of a modified Beer-Lambert law (Obrig and 
Villringer, 2003) using the proprietorial software. The concentration changes in the total 
levels of haemoglobin (total-Hb) were derived by summing the concentration changes in 
oxygenated (oxy-Hb) and deoxygenated (deoxy-Hb) haemoglobin. NIRS haemodynamic 
parameters have previously been shown to correspond strongly with the functional 
magnetic resonance imaging (fMRI) blood oxygen level dependent (BOLD) signal (Huppert et 
al., 2006; Steinbrink et al., 2005). NIRS has been used extensively as a technique for 
multiple-channel imaging of task related brain activity over relevant areas of the head 
(Schecklmann et al., 2008), including in groups suffering from potential decrements in CBF 
(Schecklmann et al., 2007).  
In this study, given the extended recording period and the investigational aims, a simple two 
emitter/optode pair configuration was utilised (i.e. 2 channels). The emitter/optode pairs 
were positioned over the left and right frontal cortex using a standard optode holder 
headband, which separated the pairs from each other by 4cm. Each pair therefore collected 
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data from an area of prefrontal cortex that included the areas corresponding to the 
International 10-20 system Fp1 ad Fp2 EEG positions. 
The NIRS data output was time stamped at the start of each task segment to assure that 
data corresponded to the relevant epoch of task performance. 
 
Cognitive tasks: 
In order to assess the contribution that activation of the brain region under investigation 
made towards any treatment related effects on CBF, a selection of tasks that engender 
either higher or lower activation of the frontal cortex were employed. This paradigm was 
adopted, in part, to assess the differential CBF effects elicited by task demand (with 
frontal cortex CBF observed to increase with cognitive workload (Son et al., 2005; 
Tsujimoto et al., 2004)) and how this interacted with treatment, but also in order to elicit 
greater cognitive demand in the young participants employed here, who are presumably 
at their cognitive peak. Thus any treatment related cognitive effects are liable to be subtle 
and likely amplified under greater cognitive demand. The ‘low activation’ tasks comprised 
two simple reaction time tasks (Odd-ball reaction time and Simple reaction time). The ‘high 
activation’ tasks (Serial subtractions, Rapid Visual Information Processing, and Stroop tasks) 
all entail a higher cognitive workload and have all been shown to increase activity 
specifically in the prefrontal cortex (Schroeter et al., 2002; Drummond et al., 1999; Bench et 
al., 1993; Lawrence et al., 2002).  
 
The computerised battery of cognitive tasks comprised: 
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Serial subtractions: This task (for further details see: (Kennedy et al., 2008)), at baseline, 
comprised 2 minutes of Serial 3s followed by 2 minutes of serial 7s subtractions with the 
task length extending to 3.5 minutes for each task at post dose. At the start of each 
subtraction task a standard instruction screen informed the participant to mentally count 
backwards in 3s or 7s, as quickly and accurately as possible, using the keyboard’s linear 
number keys to enter each response. Participants were also instructed verbally at the outset 
that if they were to make a mistake they should carry on subtracting from the new incorrect 
number. A random starting number between 800 and 999 was presented on the computer 
screen, which was cleared by the entry of the first response. Each three-digit response was 
represented on screen by an asterisk. Pressing the enter key signalled the end of each 
response and cleared the three asterisks from the screen. Performance data (total number 
of subtractions and number of errors) were calculated for the Serial 3s and 7s elements 
separately. In the case of incorrect responses, subsequent responses were scored as 
positive if they were correct in relation to the new number. 
Oddball reaction time task: Two distinct visual stimuli (150 x 150 pixels) were presented on 
screen at regular intervals. The frequent non-target stimuli (n = 200) were red circles and 
the less frequent target stimuli (n = 40) were green squares. There was also an infrequent 
distracter in the form of a blue triangle. The frequent and rare stimuli were randomly 
presented during the task with each presentation consisting of a blank screen for 100 ms, 
stimulus presentation for 100 ms and finally a blank screen for 1600 ms. During the task the 
participants had to ignore frequent non-target stimuli and respond by pressing the ‘space 
bar’ on a standard computer keyboard when the less-frequent target stimuli (i.e. the green 
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square) appeared. This task is scored for reaction time to target stimuli and lasted ~3 
minutes and 30 seconds at baseline and 7 minutes and 30 seconds at post dose.  
Rapid Visual Information Processing task [RVIP]: This task requires the participant to 
monitor a continuous series of single digits for targets of three consecutive odd or three 
consecutive even digits. The digits are presented on the computer screen at the rate of 100 
per minute in pseudo-random order and the participant responds to the detection of a 
target string by pressing the space bar as quickly as possible. The task is continuous and 
lasted for 2 minutes at baseline and 7 minutes at post dose, with 8 correct target strings 
being presented in each minute. The task is scored for number of target strings correctly 
detected, average reaction time for correct detections, and number of false alarms. 
Stroop task: Participants were required to complete a computerised version of the classic 
Stroop task in which words describing colours (red, blue, yellow, green) were presented 
either in the same ‘congruent’ font, or a different ‘incongruent’ font. Participants had to 
identify the colour of the font that the word was written in, rather than the colour that the 
word was describing, via a response box with coloured keys.  For example, if the word red 
appeared on the screen and was written in a blue font then the correct response would be 
to press the blue key. This task lasted for 2 minutes at baseline and 7 minutes at post dose. 
The outcomes for the task were the number of correct responses and the average response 
times for congruent and incongruent stimuli.  
Simple reaction time: The participant was instructed to continuously monitor the laptop 
screen and to press the space bar as quickly as possible every time a single stimulus 
(upwards pointing arrow) was presented. The task length was 2 minutes at baseline and 7 
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minutes and post dose and the task outcome was average reaction time (msec) response to 
the stimuli. 
Mood Visual Analogue Scales (Mood VAS): Prior to completing baseline and post dose tasks 
participants were required to rate how ‘ relaxed’, ‘alert’, ‘jittery’, ‘tired’, ‘tense’ and 
‘mentally fatigued’ they felt by placing a cross with the mouse and cursor on a ~100mm on-
screen line between the descriptors ‘not at all’ and ‘extremely’. They also rated their ‘overall 
mood’ on a scale anchored by ‘very poor’ to ‘very good’ and their levels of ‘headache’ 
between ‘not at all’ and ‘extremely’. The VAS were scored as % along the line denoting more 
of the relevant adjective. 
 
Procedure: 
Each participant was required to attend the laboratory on four occasions. The first of these 
was an initial screening/training visit during which participants provided written informed 
consent, were screened with regards the study exclusion/inclusion criteria, briefed with 
regards compliance requirements, and given training in completing the cognitive tasks. This 
visit was followed within 14 days by the first of three active study mornings.  
On each of the three active study mornings, which were conducted 7 days apart, 
participants attended the laboratory at 11:00am or 2:45pm having eaten nothing in the 
preceding 2 hours and provided confirmation of continued compliance with the 
inclusion/exclusion requirements. After a 5 minute seated resting period heart rate was 
measured and a blood pressure reading was taken, after which participants completed 
Mood VAS. Following a three minute resting period participants were verbally instructed to 
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start the period of baseline cognitive task performance which comprised shortened versions 
of the cognitive tasks: Serial subtractions (3s - 2 mins, 7s – 2 mins);  Oddball reaction time 
task (3 minutes and 30 seconds); Stroop task (2 mins); Simple reaction time (2 mins) and 
RVIP (2 mins). Participants then rested for 5 minutes after which they consumed their 
treatment for that day, following which they sat quietly, watching one of a selection of non-
arousing DVDs, during a 45 minutes ‘absorption’ period. The Tmax of green tea polyphenols 
varies hugely in the literature, ranging from 0.5- (Leenen et al., 2000; Pietta et al., 1998) to 
4 hours (Nakagawa et al., 1997) depending on the form of catechin/s. Huge individual 
variability in metabolism also influences T- and Cmax. Thus, in the absence of consistent 
bioavailability information, 45 minutes was chosen as a somewhat exploratory absorption 
period. 
After completing the Mood VAS again participants were verbally instructed to start the 
period of post dose task performance which comprised six 7 minute epochs of individual 
task performance (plus up to an additional 30 seconds for those tasks that depended on 
speed of response). The task order was Serial subtractions (3s then 7s - 3.5 minutes each), 
Oddball reaction time task (7 minutes and 30 seconds), RVIP, Oddball reaction time task, 
Stroop task, and then the Simple reaction time task (all 7 minutes) (i.e. ~ 42 minutes of 
continuous task performance). After a 3 minute rest period heart rate was measured and a 
blood pressure reading was taken from participants. NIRS data was captured throughout. 
The timelines and running order of the testing session are shown in Figure 1. 
 
Figure 1 about here 
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Statistics 
The analyses of NIRS data were conducted with Minitab 15 for Windows (Minitab Inc, State 
College, PA) and behavioural data with SPSS 16.0 for Windows (SPSS Inc, Chicago, IL). NIRS 
data was converted to ‘change from baseline’ (calculated from the final 3 minutes of the 5 
minute resting period immediately pre-treatment) and data collected from the left and right 
hemispheres were averaged. Data from the ‘resting/absorption’ period (minutes 1 to 45) 
and the task performance period (minutes 46 to 87) were analyzed separately. Data from 
the ‘resting/absorption’ period was averaged across 6 equal 7.5 minute epochs and 
analysed by two-way repeated measures ANOVA (epoch x treatment). Data from the task 
period data was averaged across the 7 min task period, also giving 6 epochs, each of 7 
minutes duration. This data was analysed by two-way repeated measures ANOVA (task 
[epoch] x treatment). In the case of those analyses that showed a significant main effect of 
treatment or a task/epoch x treatment interaction, planned comparisons of data from each 
task or epoch were then made between placebo and each of the EGCG treatment groups 
using t tests calculated with the Mean Squares Error from the ANOVA. A Bonferroni 
adjustment was made for multiplicity (Kepple, 1991). As the duration of each complete 
epoch of averaged NIRS data entered into the analysis was substantially longer than the 
potential physiological oscillations that can cause drift in shorter periods of NIRS recording 
(Hoshi, 2007) no adjustment was required to control for this phenomena. 
Prior to the primary analyses, the distribution of the NIRS data was found to have a 
significant negative skew. The data was therefore normalised by inversion followed by a 
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Log(10) transformation. A further ANOVA was then conducted for each measure to confirm 
that any significant differences found on the ANOVAs of raw data were retained following 
normalisation.  
Task performance data were analysed by within subjects ANCOVA (treatment) with pre-
treatment performance included as a co-variate for each individual task/measure (Serial 3s, 
Serial 7s, RVIP, Stroop, Simple reaction time, Oddball and Mood VAS). 
Blood pressure data (systolic, diastolic and heart rate) were analysed by within subjects 
ANOVA (treatment x pre-post treatment).  
 
 
RESULTS 
Cognitive performance and mood 
No significant treatment related differences were observed on any of the cognitive or mood 
measures.   
 
Heart rate and blood pressure 
There was a significant reduction in heart rate across conditions between the initial pre-
dose measurement and the measurement taken at the end of testing (approximately 90 
minutes post-dose) [F (1, 26) = 8.15, p < 0.05]. There was no interaction between treatment 
and assessment (F < 1).  
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NIRS 
Deoxygenated haemoglobin: There were no significant differences in terms of deoxy-Hb 
during either the resting or task performance periods. 
Oxygenated haemoglobin: There was no effect of treatment during the absorption period. 
However, on the initial ANOVA, there was a significant main effect of treatment on oxy-Hb 
levels during the task period [F (2, 52) = 3.41, p < 0.05]. The analysis of normalised data 
confirmed that this effect survived log transformation [F (2, 52) = 3.19, p < 0.05]. Reference 
to the planned comparisons of the raw data means from each epoch showed that, whereas 
there were no significant differences associated with the higher dose of EGCG, the lower 
dose lead to a reduction in oxy-HB during each of the six 7 minute task periods [t’s (260) = 
4.83 – 5.84, all p < 0.01].  
Total levels of haemoglobin: Similarly, there was no effect of treatment on total-Hb during 
the absorption period. However, on the initial ANOVA, there was a significant main effect of 
treatment on total-Hb during the task period [F (2, 52) = 3.53, p < 0.05]. The analysis of 
normalised data confirmed that this effect survived log transformation [F (2, 52) = 3.38, p < 
0.05]. Reference to the planned comparisons of the raw data means from each epoch 
showed that, whereas there were no significant differences associated with the higher dose 
of EGCG, the lower dose lead to a reduction in oxy-HB during each of the six 7 minute task 
periods [t’s (260) = 4.96 – 6.85, all p < 0.01]. 
There was no interaction between task and treatment with regards any of the NIRS 
parameters. A graphic representation of the mean total-Hb response to the first three 
Page 16 of 32
http://mc.manuscriptcentral.com/hup
Human Psychopharmacology: Clinical and Experimental
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
17 
 
minutes of task performance (averaged across tasks) are shown in Figure 2. The mean 
concentration changes (plus SEM) during the absorption and task periods for deoxy-Hb, and 
total-Hb are shown in Figure 3. 
 
Figure 2 and Figure 3 about here 
 
 
DISCUSSION 
The results here show that, in comparison to placebo, the consumption of EGCG resulted in 
modulation of CBF parameters in the frontal cortex during task performance. This effect was 
restricted to the lower (135 mg) dose of EGCG and was seen as a reduction in CBF during the 
task period, as indexed by the concentration of haemoglobin (total-Hb), with an identical 
pattern of results seen in terms of oxy-Hb. With regards deoxy-Hb, no effect of treatment 
was observed. These CBF effects were not associated with any significant modulation of 
either cognitive performance or mood and, whilst they were only evident during the task 
performance period, there was no indication that the treatment related effects were 
predicated on the amount of activation of the frontal cortex associated with the tasks that 
were assumed to engender ‘high’ and ‘low’ activation of this brain region.   
Whilst the results here show clearly that EGCG can modulate aspects of brain function, in 
the absence of any modulation of behavioural parameters it is difficult to say whether the 
comparative reduction in CBF seen here represents a net benefit or decrement in terms of 
brain function. On the most simplistic level optimal performance should require increased 
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delivery of blood, and therefore metabolic substrates, during neuronal demand. A recent 
electroencephalography (EEG) study investigating the electrical brain response to EGCG in 
healthy human participants, however, corresponds with the results presented in this 
paper; finding that although 300mg orally consumed EGCG evinced increased cerebral 
activity in the form of alpha, beta and theta waves, no task performance effects were 
observed (Scholey et al., In press). 
Overall CBF has been shown to decline throughout adulthood (Parkes et al., 2004), and both 
reduced basal CBF (Bertsch et al., 2009) and task specific CBF responses (Sorond et al., 2008) 
are associated with declining performance during healthy ageing. Similarly, compromised 
CBF has also been suggested as a key causal factor in the reduced cognitive function seen 
with age and in a number of neurodegenerative diseases (Farkas et al., 2002). However, 
whilst the reduced CBF seen here may therefore be interpreted as a detrimental effect it 
may also reflect a reduced requirement for blood flow due to a further unidentified factor 
improving other aspects of brain function. An alternative possibility is that the reduced CBF 
might be negative in itself, but is compensated for by another, unmeasured mechanism. As 
an example of this, caffeine is a vasoconstrictor that has been shown to reduce CBF as 
assessed by a number of methods (Field et al., 2003; Lunt et al., 2004; Sigmon et al., 2009) 
including the NIRS methodology employed here (Kennedy and Haskell, 2011). In the case of 
caffeine the vasoconstriction is predicated on the blockade of adenosine A2A receptors 
throughout the cerebro-vascular system, whilst concomitant blockade of  A1 receptors 
throughout the brain increases neuronal firing rate (Laurienti et al., 2003), leading 
ultimately to net improvements in alertness and attention task performance despite 
reduced CBF.    
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In terms of specific mechanisms underlying the effects seen here, it is interesting to note 
that in a similar study we previously assessed the effects of single doses (250 mg, 500 mg) of 
the polyphenol resveratrol in healthy human participants and observed a linear, dose-
related increase in CBF in the frontal cortex, during the performance of the mentally 
demanding, ‘frontal’ Serial subtraction and RVIP tasks (Kennedy et al., 2010). The opposite 
effect on CBF seen here following EGCG may well be related to differential effects on the 
vaso-relaxatory process associated with NOS. In the case of resveratrol, evidence suggests 
that it increases NO synthesis via eNOS (Tsai et al., 2007) and nNOS (Hung et al., 2004) and 
consequently has evinced consistent effects in terms of NO related peripheral vaso-dilation 
in animals (Lekakis et al., 2005; Zou et al., 2003) and humans (Wong et al., 2011) and 
increased CBF in rats (Lu et al., 2006) and humans (Kennedy et al., 2010). EGCG on the other 
hand has a less clear cut pattern of effects on vascular/microvascular tone, with some 
evidence of improved peripheral endothelial function in humans (Widlansky et al., 2007) but 
demonstrations ex vivo of both vaso-constriction (Sanae et al., 2002) and dilation (Alvarez et 
al., 2006). It has also been shown to up-regulate eNOS (Widlansky et al., 2007) but inhibit 
nNOS (Lin and Lin, 1997). Whilst both eNOS and nNOS are both found in brain tissue (Toda 
and Okamura, 2003), it is nNOS derived NO which has been observed to make the greatest 
contribution to activity dependent vasodilation (Santizo et al., 2000). Interestingly, the nNOS 
isoform has also recently been associated with peripheral vasodilatory responses (Melikian 
et al., 2009) including that elicited by cognitive task performance (Stroop) in healthy human 
participants (Seddon et al., 2008). EGCGs inhibition of this isoform might therefore underlie 
the less than straightforward effects seen, both in terms of the literature pertaining to 
peripheral vasodilation, and the potential cerebral vasoconstriction see in the current study. 
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This same inconsistency may also explain the dose specific effect seen here. EGCG’s effects 
on vascular tone have been shown to differ both over time and with dose. So, for instance, 
EGCG has been shown to have transient peripheral vasoconstricting effects, followed by 
vasodilation (Alvarez et al., 2004), and animal data confirms that at low doses green tea 
catechins have vasoconstricting properties (Shen et al., 2003) and that at higher doses they 
induce vasorelaxation (Lorenz et al., 2004). Whilst the differential effects of EGCG on the 
eNOS and nNOS isoforms makes it difficult to extrapolate CNS effects from the peripheral 
data it may well be that the lowest dose has cerebral vasoconstriction properties that are 
simply not seen at the higher dose, and that a further increase in dose may result in 
increased CBF. Naturally these possibilities will need to be explored further, and it would be 
prudent to investigate longer time courses and both lower and higher doses in order to 
document the full profile of EGCG’s vasoregulatory properties. Interestingly, the migraine 
treatment Sumatriptan also functions via modulation of NO, demonstrating both 
vasorelaxing and a vasoconstricting properties (Elhusseiny and Hamel, 2001), and does not 
have a straightforward dose response profile (Fowler et al., 1991). It is also interesting to 
note that evidence from dose ranging studies in humans shows that a wide range of 
phytochemicals and herbal extracts have greater impacts on cognitive performance and 
physiological parameters at lower, rather than higher, doses. Recent examples of such 
findings from dose ranging studies include sage (Scholey et al., 2008; Tildesley et al., 2003), 
guaraná (Haskell et al., 2007), cocoa- flavanols (Scholey et al., 2010) and ginseng (Reay et 
al., 2005). 
One aspect of the current study that was somewhat disappointing was the failure to 
demonstrate clear, differential haemodynamic responses to the more demanding ‘high 
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activation’ and less demanding ‘low activation’ tasks, whereby the former might have been 
expected to engender higher total-Hb and lower deoxy-Hb. This manipulation was included 
to try to differentiate whether any treatment related effects on CBF parameters were 
specifically related to the level of activation, and therefore NO driven increases in blood 
flow requirements, of the brain region. However, there was no evidence of any 
treatment/task interaction, and the main effect of EGCG on CBF would appear, from the 
data here, to be a general one across tasks, irrespective of cognitive workload. Reference to 
Figure 3 shows a simple pattern of declining concentrations of total-Hb throughout the task 
period, irrespective of treatment. This apparent lack of sensitivity to task intensity could be 
as a consequence of only utilizing a 2 channel NIRS system, thus reducing spatial 
resolution. Future studies might therefore consider using additional channels and 
recording at other locations of the cortex to assess if supplementary regions are involved 
in the completion of these tasks.  
Task length and/or perception of demand/difficulty could also explain the lack of CBF 
sensitivity to tasks. Reference to the finer grained analysis shown in Figure 2, which 
presents the total-Hb data (averaged across tasks) for the first three minutes of task 
performance in 10 second epochs, shows that total-Hb underwent the expected increase 
during the first minute of performing each task, but that this was followed by a gradual 
decline throughout the remainder of each task. This does suggest that the overall pattern of 
haemodynamic responses was due to the extended length of the tasks employed, and that 
employing shorter, more demanding tasks may be a more effective approach to 
engendering a long period of increased haemodynamic response. Alternatively, it is also 
notable that heart rate fell significantly across all three conditions from pre-dose to 90 
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minutes post-dose and it is possible that this reflects a simple reduction in physiological 
arousal between arriving at the laboratory and completing the assessment. Future research 
using this method of assessing CBF might usefully include an extended rest period before 
recording commences, with heart rate monitoring throughout.   
One key issue regarding EGCG and other polyphenols is that of the low bioavailability of the 
parent compound (Lee et al., 2002), which questions the relevance to humans of much of 
the in vitro research conducted with concentrations of EGCG that would not be attainable  
in mammals. The paradoxical finding of multifarious in vivo effects despite this poor 
bioavailability suggests that the metabolites of EGCG (and other polyphenols) may be active 
in their own right: the substantial amounts of two catechin metabolites (4’- O- MeEGC, (-) -
5- (3’, 4’, 5’- trihydroxyphenyl) - γ- valerolactone (M4) and (-) -5- (3’, 4’- dihydroxyphenyl) - 
γ- valerolactone (M6)) detected in human plasma and urine would certainly suggest that 
they could possess biological activities (Lee et al., 2002). Alternatively EGCG may operate 
principally via secondary mechanisms, for instance NO synthesis, and as such only relatively 
small concentrations may be required to instigate a cascade of cellular events. In this 
respect it is interesting to note that EGCG has been shown to cross the blood-brain barrier 
in rodents (Suganuma et al., 1998). Further research is certainly required to fully explore the 
biotransformation of polyphenols in humans in order to better appreciate their sources of 
bioactivity.    
In conclusion, the results here demonstrate that the green tea catechin EGCG is able to 
modulate CBF in healthy human participants, with decreased concentrations of 
haemoglobin seen in the frontal cortex during cognitive task performance following the 
lower (135 mg) of two doses that were administered. However, the lack of effects on 
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cognitive performance and mood make it difficult to interpret the modulation in CBF as 
either a positive or negative modulation of overall brain function. With these results in 
mind, future research might usefully investigate the effects of both lower and higher doses 
of EGCG on both cerebral and peripheral blood flow. The combination of methodologies 
may elucidate the comparative roles of eNOS and nNOS in any vaso-regulatory properties of 
EGCG. It would also be prudent to image other regions of the brain during the 
performance of ‘frontal’ tasks and ascertain whether other areas of the brain are involved 
and sharing the burden of increased workload. Investigating the effects of longer 
treatment periods and the behavioural/CBF effects of this polyphenol in cohorts that may 
be more susceptible to modulation would also seem to be warranted by the current 
investigation. 
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Figure 1. Timelines of each assessment. Blood pressure and heart rate were measured. 
Participants then completed one repetition of the tasks to establish baseline performances. 
After a 5 minute resting period, they received their day’s treatment and, after a 45 minute 
resting/absorption period, they completed a longer version of each of the baseline tasks. 
After completion heart rate and blood pressure were measured again. Near- infrared 
spectroscopy (NIRS) data were collected throughout with the pre-treatment resting phase 
used to baseline- adjust all pre-treatment data. 
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Figure 2. Total-Hb data, averaged across the tasks, and shown for the first three minutes of task 
performance in 10 second epochs. 
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Figure 3.  Mean (plus SEM) changes in concentrations of deoxy-Hb and Total-Hb during the 
absorption period and six 7 minute task periods (** = p < 0.01, Bonferroni adjusted planned 
comparisons).  
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